208 related articles for article (PubMed ID: 37462020)
1. [Analysis of risk factors of radiation-induced toxicity in limited-stage small cell lung cancer treated with hypofractionated intensity-modulated radiotherapy].
Zhao JJ; Bi N; Zhang T; Wang JY; Deng L; Wang X; Chen DF; Dai JR; Wang LH
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):627-633. PubMed ID: 37462020
[No Abstract] [Full Text] [Related]
2. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS
Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
[TBL] [Abstract][Full Text] [Related]
4. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
[TBL] [Abstract][Full Text] [Related]
5. Correlation of dosimetric and clinical factors with the development of esophagitis and radiation pneumonitis in patients with limited-stage small-cell lung carcinoma.
Giuliani ME; Lindsay PE; Kwan JY; Sun A; Bezjak A; Le LW; Brade A; Cho J; Leighl NB; Shepherd FA; Hope AJ
Clin Lung Cancer; 2015 May; 16(3):216-20. PubMed ID: 25532963
[TBL] [Abstract][Full Text] [Related]
6. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
Singh AK; Lockett MA; Bradley JD
Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for esophagitis after hypofractionated palliative (chemo) radiotherapy for non-small cell lung cancer.
Nieder C; Imingen KS; Mannsåker B; Yobuta R; Haukland E
Radiat Oncol; 2020 May; 15(1):91. PubMed ID: 32357936
[TBL] [Abstract][Full Text] [Related]
8. Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer.
Jaksic N; Chajon E; Bellec J; Corre R; Ricordel C; de Latour B; Lena H; Schick U; de Crevoisier R; Castelli J
Radiat Oncol; 2018 Aug; 13(1):147. PubMed ID: 30103774
[TBL] [Abstract][Full Text] [Related]
9. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
Ren XJ; Wang L; Han C; Liu LL
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
[No Abstract] [Full Text] [Related]
10. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
[TBL] [Abstract][Full Text] [Related]
11. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
[TBL] [Abstract][Full Text] [Related]
12. Clinical and dosimetric predictors of radiation-induced esophageal toxicity.
Maguire PD; Sibley GS; Zhou SM; Jamieson TA; Light KL; Antoine PA; Herndon JE; Anscher MS; Marks LB
Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):97-103. PubMed ID: 10477012
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis.
Sun H; Liu C; Zhang J; Yang G; Han D; Liu T; Huang W; Li B
Radiother Oncol; 2022 Jul; 172():140-146. PubMed ID: 35101460
[TBL] [Abstract][Full Text] [Related]
14. Multivariable normal-tissue complication modeling of acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-)radiotherapy.
Wijsman R; Dankers F; Troost EG; Hoffmann AL; van der Heijden EH; de Geus-Oei LF; Bussink J
Radiother Oncol; 2015 Oct; 117(1):49-54. PubMed ID: 26341608
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.
Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
[TBL] [Abstract][Full Text] [Related]
17. Excluding PTV from lung volume may better predict radiation pneumonitis for intensity modulated radiation therapy in lung cancer patients.
Meng Y; Yang H; Wang W; Tang X; Jiang C; Shen Y; Luo W
Radiat Oncol; 2019 Jan; 14(1):7. PubMed ID: 30642354
[TBL] [Abstract][Full Text] [Related]
18. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.
Ma L; Qiu B; Li Q; Chen L; Wang B; Hu Y; Liu M; Zhang L; Huang Y; Deng X; Xia Y; Lin M; Liu H
Radiat Oncol; 2018 Jul; 13(1):130. PubMed ID: 30016978
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the incidence of ≥ grade 2 radiation pneumonitis between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy in patients with unresectable non-small cell lung cancer treated with durvalumab after concurrent chemoradiotherapy.
Masuo M; Shinohara E; Kitano M; Maruta R; Chonabayashi S; Endo S; Matumoto S; Nishiyama N; Machitori Y; Kobayashi M
Jpn J Clin Oncol; 2024 Mar; 54(3):312-318. PubMed ID: 38010609
[TBL] [Abstract][Full Text] [Related]
20. Initial report on feasibility of PET/CT-based image-guided moderate hypofractionated thoracic irradiation in node-positive non-small cell lung Cancer patients with poor prognostic factors and strongly diminished lung function: a retrospective analysis.
Eze C; Taugner J; Roengvoraphoj O; Schmidt-Hegemann NS; Käsmann L; Wijaya C; Belka C; Manapov F
Radiat Oncol; 2019 Sep; 14(1):163. PubMed ID: 31484542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
